Cite
Clamp AR, Lorusso D, Oza AM, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Int J Gynecol Cancer. 2021;31(7):949-958doi: 10.1136/ijgc-2020-002240.
Clamp, A. R., Lorusso, D., Oza, A. M., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Scambia, G., Leary, A., Holloway, R. W., Amenedo Gancedo, M., Fong, P. C., Goh, J. C., O'Malley, D. M., Armstrong, D. K., Banerjee, S., García-Donas, J., Swisher, E. M., Cameron, T., Goble, S., Coleman, R. L., & Ledermann, J. A. (2021). Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 31(7), 949-958. https://doi.org/10.1136/ijgc-2020-002240
Clamp, Andrew R, et al. "Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 31,7 (2021): 949-958. doi: https://doi.org/10.1136/ijgc-2020-002240
Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Int J Gynecol Cancer. 2021 Jul;31(7):949-958. doi: 10.1136/ijgc-2020-002240. Epub 2021 Jun 08. PMID: 34103386.
Copy
Download .nbib